A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

	A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
	Wang, Jing ; Lou, Hanmei ; Cai, Hong-Bing ; Huang, Xin ; Li, Guiling ; Wang, Li ; Liu, Ting ; Liu, Wei ; Li, Baiyong ; Xia, Yu
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2022-06-01
卷号	40
ISSN号	0732-183X
资助项目	Akeso
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000863680300217
资助机构	Akeso
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129945]
专题	中国科学院合肥物质科学研究院
作者单位	1.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China 2.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China 3.Hunan Canc Hosp, Changsha, Peoples R China 4.Wuhan Univ, Dept Gynecol Oncol, Zhongnan Hosp, Wuhan, Peoples R China 5.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 6.Akeso Biopharma Inc, Zhongshan, Peoples R China 7.Henan Canc Hosp, Zhenzhou, Peoples R China
推荐引用方式 GB/T 7714	Wang, Jing,Lou, Hanmei,Cai, Hong-Bing,et al. A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Wang, Jing.,Lou, Hanmei.,Cai, Hong-Bing.,Huang, Xin.,Li, Guiling.,...&Xia, Yu.(2022).A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC)..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Wang, Jing,et al."A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).".JOURNAL OF CLINICAL ONCOLOGY 40(2022).